102 related articles for article (PubMed ID: 24825416)
1. A clinical utility index for selecting an optimal insulin dosing algorithm for LY2605541 in patients with type 2 diabetes pretreated with basal insulin.
Manner DH; Luo J; Qu Y; Berry S; Gaydos BL; Jacober SJ
Diabetes Technol Ther; 2014 Aug; 16(8):499-505. PubMed ID: 24825416
[TBL] [Abstract][Full Text] [Related]
2. Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine.
Bergenstal RM; Rosenstock J; Bastyr EJ; Prince MJ; Qu Y; Jacober SJ
Diabetes Care; 2014; 37(3):659-65. PubMed ID: 24198302
[TBL] [Abstract][Full Text] [Related]
3. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.
Bergenstal RM; Rosenstock J; Arakaki RF; Prince MJ; Qu Y; Sinha VP; Howey DC; Jacober SJ
Diabetes Care; 2012 Nov; 35(11):2140-7. PubMed ID: 22787177
[TBL] [Abstract][Full Text] [Related]
4. Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8.
Harris C; Forst T; Heise T; Plum-Mörschel L; Watkins E; Zhang Q; Fan L; Garhyan P; Porksen N
Diabetes Technol Ther; 2017 Aug; 19(8):463-470. PubMed ID: 28817342
[TBL] [Abstract][Full Text] [Related]
5. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects.
Sinha VP; Choi SL; Soon DK; Mace KF; Yeo KP; Lim ST; Howey DC
J Clin Pharmacol; 2014 Jul; 54(7):792-9. PubMed ID: 24504686
[TBL] [Abstract][Full Text] [Related]
6. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.
Sinha VP; Howey DC; Choi SL; Mace KF; Heise T
Diabetes Obes Metab; 2014 Apr; 16(4):344-50. PubMed ID: 24118909
[TBL] [Abstract][Full Text] [Related]
7. PEGylated insulin Lispro, (LY2605541)--a new basal insulin analogue.
Caparrotta TM; Evans M
Diabetes Obes Metab; 2014 May; 16(5):388-95. PubMed ID: 23941279
[TBL] [Abstract][Full Text] [Related]
8. Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM.
Jacober SJ; Rosenstock J; Bergenstal RM; Prince MJ; Qu Y; Beals JM
Diabetes Obes Metab; 2014 Apr; 16(4):351-6. PubMed ID: 24719911
[TBL] [Abstract][Full Text] [Related]
9. AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes.
Edelman SV; Liu R; Johnson J; Glass LC
Diabetes Care; 2014 Aug; 37(8):2132-40. PubMed ID: 24742662
[TBL] [Abstract][Full Text] [Related]
10. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
[TBL] [Abstract][Full Text] [Related]
11. Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trial.
Morrow LA; Hompesch M; Jacober SJ; Leng Choi S; Qu Y; Sinha VP
Diabetes Obes Metab; 2016 Nov; 18(11):1065-1071. PubMed ID: 27169522
[TBL] [Abstract][Full Text] [Related]
12. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
[TBL] [Abstract][Full Text] [Related]
13. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study.
Rosenstock J; Bergenstal RM; Blevins TC; Morrow LA; Prince MJ; Qu Y; Sinha VP; Howey DC; Jacober SJ
Diabetes Care; 2013 Mar; 36(3):522-8. PubMed ID: 23193209
[TBL] [Abstract][Full Text] [Related]
14. Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes.
Johansen RF; Søndergaard E; Linnebjerg H; Garhyan P; Lam ECQ; Porksen N; Jacober SJ; Nielsen S
Diabetes Obes Metab; 2018 Feb; 20(2):419-426. PubMed ID: 28817248
[TBL] [Abstract][Full Text] [Related]
15. Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs.
Dungan KM; Buse JB; Herman WH; Arakaki RF; Jiang HH; Jacobson JG; Fahrbach JL
Diabetes Res Clin Pract; 2012 Jun; 96(3):e66-9. PubMed ID: 22421598
[TBL] [Abstract][Full Text] [Related]
16. Simulation-Based Evaluation of Dose-Titration Algorithms for Rapid-Acting Insulin in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antihyperglycemic Medications.
Ma X; Chien JY; Johnson J; Malone J; Sinha V
Diabetes Technol Ther; 2017 Aug; 19(8):483-490. PubMed ID: 28700249
[TBL] [Abstract][Full Text] [Related]
17. How much do I give? Dose estimation formulas for once-nightly insulin glargine and premeal insulin lispro in type 1 diabetes mellitus.
King AB; Clark D; Wolfe GS
Endocr Pract; 2012; 18(3):382-6. PubMed ID: 22440988
[TBL] [Abstract][Full Text] [Related]
18. Effect of basal insulin dosage on blood glucose concentration in ambulatory surgery patients with type 2 diabetes.
Demma LJ; Carlson KT; Duggan EW; Morrow JG; Umpierrez G
J Clin Anesth; 2017 Feb; 36():184-188. PubMed ID: 28183563
[TBL] [Abstract][Full Text] [Related]
19. Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
Porksen N; Linnebjerg H; Garhyan P; Lam EC; Knadler MP; Jacober SJ; Hoevelmann U; Plum-Moerschel L; Watkins E; Gastaldelli A; Heise T
Diabetes Obes Metab; 2017 Apr; 19(4):482-488. PubMed ID: 27888561
[TBL] [Abstract][Full Text] [Related]
20. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
Xie L; Wei W; Pan C; Baser O
J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
